Your browser doesn't support javascript.
loading
Botulinum Toxin Therapy for Nonmotor Aspects of Parkinson's Disease.
Slawek, Jaroslaw; Madalinski, Mariusz.
Affiliation
  • Slawek J; Medical University of Gdansk, Gdansk, Poland; St. Adalbert Hospital, "Copernicus" Ltd., Gdansk, Poland. Electronic address: jaroslawek@gumed.edu.pl.
  • Madalinski M; The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom.
Int Rev Neurobiol ; 134: 1111-1142, 2017.
Article in En | MEDLINE | ID: mdl-28805566
The medical treatment of Parkinson's disease (PD) is symptomatic both in terms of motor and nonmotor aspects. The nonmotor symptoms therapy should be taken into account as many of them negatively influence the quality of life and are treatable. Botulinum neurotoxin (BoNT) offers effective treatment for drooling and bladder dysfunctions and alternative treatment for constipation and pain related to parkinsonism. BoNT for drooling is probably the best-documented therapy for nonmotor symptoms by clinical trials. Ultrasound-guided injections into parotid and submandibular glands can be recommended as the first line treatment, especially when anticholinergic oral medications are not indicated due to the risk of confusion, cognitive decline, or psychosis. BoNT therapy of constipation and neurogenic bladder is not so well evidenced and the latter indication is based on positive effects in clinical trials in multiple sclerosis and posttraumatic spine injuries. BoNT injections into the salivary glands or bladder are effective and safe with relatively low risk of complications. Authors reviewed the literature on the use of BoNT for all nonmotor aspects of PD, showed their position in guidelines and systematic reviews and gave the practical remarks on injection techniques and dosing.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Botulinum Toxins / Acetylcholine Release Inhibitors Type of study: Clinical_trials / Guideline Aspects: Patient_preference Limits: Humans Language: En Journal: Int Rev Neurobiol Year: 2017 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Parkinson Disease / Botulinum Toxins / Acetylcholine Release Inhibitors Type of study: Clinical_trials / Guideline Aspects: Patient_preference Limits: Humans Language: En Journal: Int Rev Neurobiol Year: 2017 Document type: Article Country of publication: United States